Sami Uwaydat
Concepts (253)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 10 | 2024 | 56 | 5.280 |
Why?
| | Eye Injuries | 5 | 2024 | 24 | 3.200 |
Why?
| | Visual Acuity | 14 | 2024 | 144 | 2.910 |
Why?
| | Vitrectomy | 11 | 2024 | 61 | 2.470 |
Why?
| | Tomography, Optical Coherence | 18 | 2024 | 109 | 2.260 |
Why?
| | Retina | 8 | 2024 | 63 | 2.040 |
Why?
| | Endophthalmitis | 3 | 2022 | 24 | 1.890 |
Why?
| | Macular Degeneration | 3 | 2024 | 28 | 1.830 |
Why?
| | Retinal Perforations | 3 | 2024 | 7 | 1.790 |
Why?
| | Diabetic Retinopathy | 3 | 2024 | 44 | 1.710 |
Why?
| | Macular Edema | 4 | 2023 | 29 | 1.560 |
Why?
| | Drug Implants | 5 | 2020 | 35 | 1.520 |
Why?
| | Retinal Degeneration | 3 | 2022 | 9 | 1.480 |
Why?
| | Chorioretinitis | 2 | 2022 | 10 | 1.480 |
Why?
| | Fungemia | 2 | 2022 | 38 | 1.460 |
Why?
| | Eye Infections, Fungal | 2 | 2022 | 20 | 1.450 |
Why?
| | Eye Diseases | 3 | 2023 | 29 | 1.280 |
Why?
| | Dexamethasone | 4 | 2020 | 438 | 1.270 |
Why?
| | Eye Infections, Bacterial | 2 | 2024 | 29 | 1.230 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 560 | 1.110 |
Why?
| | Humans | 55 | 2024 | 52483 | 1.040 |
Why?
| | Fluorescein Angiography | 7 | 2024 | 34 | 1.030 |
Why?
| | Fundus Oculi | 7 | 2024 | 24 | 0.940 |
Why?
| | Retinal Dystrophies | 2 | 2023 | 5 | 0.940 |
Why?
| | Glucocorticoids | 5 | 2020 | 235 | 0.900 |
Why?
| | Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.900 |
Why?
| | Treponema pallidum | 1 | 2024 | 9 | 0.900 |
Why?
| | Myopia, Degenerative | 1 | 2024 | 1 | 0.890 |
Why?
| | Burns, Chemical | 1 | 2024 | 9 | 0.880 |
Why?
| | Amnion | 1 | 2024 | 13 | 0.880 |
Why?
| | Syphilis | 1 | 2024 | 20 | 0.870 |
Why?
| | Glaucoma, Open-Angle | 1 | 2024 | 24 | 0.860 |
Why?
| | Retinal Vein Occlusion | 2 | 2023 | 14 | 0.850 |
Why?
| | Intraoperative Complications | 4 | 2024 | 112 | 0.780 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2022 | 7 | 0.770 |
Why?
| | Eye Proteins | 2 | 2023 | 16 | 0.770 |
Why?
| | Genetic Testing | 2 | 2020 | 129 | 0.760 |
Why?
| | Optic Atrophy | 1 | 2022 | 16 | 0.760 |
Why?
| | Retrospective Studies | 18 | 2024 | 6607 | 0.750 |
Why?
| | Giant Cell Arteritis | 1 | 2021 | 15 | 0.720 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2021 | 7 | 0.720 |
Why?
| | Databases, Factual | 2 | 2024 | 706 | 0.720 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 221 | 0.710 |
Why?
| | Laser Coagulation | 1 | 2021 | 27 | 0.700 |
Why?
| | Retinal Pigment Epithelium | 2 | 2022 | 14 | 0.700 |
Why?
| | Manikins | 1 | 2021 | 35 | 0.700 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 32 | 0.690 |
Why?
| | Multiple Sclerosis | 1 | 2021 | 72 | 0.680 |
Why?
| | Intraocular Pressure | 3 | 2024 | 59 | 0.680 |
Why?
| | Candidiasis | 1 | 2021 | 113 | 0.670 |
Why?
| | Wounds, Nonpenetrating | 1 | 2021 | 83 | 0.670 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 316 | 0.670 |
Why?
| | Choroidal Neovascularization | 2 | 2019 | 19 | 0.670 |
Why?
| | Intravitreal Injections | 7 | 2023 | 33 | 0.670 |
Why?
| | Middle Aged | 18 | 2024 | 13028 | 0.660 |
Why?
| | Anterior Chamber | 2 | 2023 | 5 | 0.660 |
Why?
| | Surgical Instruments | 1 | 2019 | 28 | 0.640 |
Why?
| | Endotamponade | 2 | 2017 | 9 | 0.600 |
Why?
| | Gaucher Disease | 1 | 2018 | 17 | 0.590 |
Why?
| | Eyelashes | 1 | 2018 | 3 | 0.580 |
Why?
| | Eyelid Diseases | 1 | 2018 | 12 | 0.570 |
Why?
| | Sulfur Hexafluoride | 1 | 2017 | 3 | 0.570 |
Why?
| | Male | 27 | 2024 | 26761 | 0.560 |
Why?
| | Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.550 |
Why?
| | Inheritance Patterns | 1 | 2017 | 22 | 0.550 |
Why?
| | Electroretinography | 6 | 2023 | 16 | 0.540 |
Why?
| | Lenses | 1 | 2016 | 5 | 0.510 |
Why?
| | Urinary Catheters | 1 | 2016 | 6 | 0.510 |
Why?
| | Suction | 1 | 2016 | 24 | 0.510 |
Why?
| | Female | 22 | 2024 | 28171 | 0.490 |
Why?
| | Incidence | 4 | 2024 | 1062 | 0.490 |
Why?
| | Mutation | 2 | 2022 | 1347 | 0.480 |
Why?
| | Bacillaceae | 1 | 2015 | 2 | 0.470 |
Why?
| | Eye Injuries, Penetrating | 1 | 2015 | 11 | 0.470 |
Why?
| | Aspirin | 1 | 2016 | 115 | 0.460 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 122 | 0.460 |
Why?
| | Choroid Neoplasms | 1 | 2014 | 6 | 0.440 |
Why?
| | Ocular Hypotension | 1 | 2013 | 2 | 0.440 |
Why?
| | Wound Healing | 2 | 2016 | 219 | 0.440 |
Why?
| | Viscosupplements | 1 | 2013 | 14 | 0.440 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 26 | 0.440 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 481 | 0.430 |
Why?
| | Head Injuries, Closed | 1 | 2013 | 7 | 0.430 |
Why?
| | Adult | 13 | 2024 | 14161 | 0.430 |
Why?
| | Hyaluronic Acid | 1 | 2013 | 38 | 0.430 |
Why?
| | Aged | 12 | 2024 | 10121 | 0.430 |
Why?
| | Disease Models, Animal | 2 | 2016 | 1478 | 0.410 |
Why?
| | Retinitis Pigmentosa | 2 | 2023 | 8 | 0.410 |
Why?
| | Physicians, Primary Care | 1 | 2013 | 46 | 0.410 |
Why?
| | Sulfonamides | 1 | 2014 | 133 | 0.410 |
Why?
| | Phacoemulsification | 3 | 2024 | 34 | 0.400 |
Why?
| | Diabetes Complications | 1 | 2013 | 122 | 0.400 |
Why?
| | Retinal Detachment | 2 | 2023 | 25 | 0.380 |
Why?
| | Acute Disease | 3 | 2023 | 373 | 0.380 |
Why?
| | Skin Neoplasms | 2 | 2014 | 505 | 0.380 |
Why?
| | Honey | 1 | 2011 | 6 | 0.370 |
Why?
| | Keratitis | 1 | 2011 | 12 | 0.370 |
Why?
| | Papilledema | 2 | 2022 | 27 | 0.370 |
Why?
| | Indoles | 1 | 2014 | 278 | 0.360 |
Why?
| | Pseudomonas Infections | 1 | 2011 | 54 | 0.360 |
Why?
| | Panuveitis | 2 | 2021 | 6 | 0.350 |
Why?
| | Melanoma | 1 | 2014 | 288 | 0.350 |
Why?
| | Clinical Competence | 1 | 2013 | 406 | 0.340 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 360 | 0.330 |
Why?
| | Risk Factors | 5 | 2024 | 3889 | 0.320 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1222 | 0.320 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 509 | 0.310 |
Why?
| | Retinal Vessels | 3 | 2024 | 15 | 0.310 |
Why?
| | Fovea Centralis | 3 | 2022 | 5 | 0.280 |
Why?
| | Child, Preschool | 5 | 2024 | 4076 | 0.260 |
Why?
| | Lens Subluxation | 1 | 2024 | 2 | 0.230 |
Why?
| | Fractals | 1 | 2024 | 9 | 0.230 |
Why?
| | Limbus Corneae | 1 | 2024 | 8 | 0.230 |
Why?
| | Child | 8 | 2024 | 7248 | 0.230 |
Why?
| | Reagins | 1 | 2024 | 3 | 0.230 |
Why?
| | Posterior Eye Segment | 1 | 2024 | 3 | 0.230 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 30 | 0.220 |
Why?
| | Subretinal Fluid | 1 | 2023 | 2 | 0.220 |
Why?
| | Scleral Buckling | 1 | 2023 | 4 | 0.220 |
Why?
| | Paracentesis | 1 | 2023 | 13 | 0.220 |
Why?
| | Choroid | 2 | 2024 | 14 | 0.220 |
Why?
| | Retinol-Binding Proteins | 1 | 2023 | 6 | 0.220 |
Why?
| | Myopia | 1 | 2023 | 9 | 0.220 |
Why?
| | Immunoglobulin G | 1 | 2024 | 195 | 0.210 |
Why?
| | Retinoschisis | 1 | 2023 | 3 | 0.210 |
Why?
| | Hemoglobin C | 1 | 2023 | 6 | 0.210 |
Why?
| | Optic Nerve Injuries | 1 | 2022 | 8 | 0.200 |
Why?
| | Young Adult | 5 | 2023 | 4329 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2020 | 182 | 0.200 |
Why?
| | Thionucleotides | 1 | 2002 | 6 | 0.200 |
Why?
| | Follow-Up Studies | 5 | 2024 | 2279 | 0.190 |
Why?
| | Pedigree | 2 | 2023 | 125 | 0.190 |
Why?
| | Scotoma | 1 | 2021 | 7 | 0.190 |
Why?
| | Vision Disorders | 2 | 2022 | 60 | 0.180 |
Why?
| | Macula Lutea | 1 | 2021 | 5 | 0.180 |
Why?
| | Albinism, Oculocutaneous | 1 | 2021 | 2 | 0.180 |
Why?
| | Temporal Arteries | 1 | 2021 | 16 | 0.180 |
Why?
| | Ophthalmoscopy | 1 | 2021 | 15 | 0.180 |
Why?
| | Choroiditis | 1 | 2020 | 9 | 0.180 |
Why?
| | Exons | 1 | 2021 | 102 | 0.170 |
Why?
| | Antiviral Agents | 1 | 2002 | 178 | 0.170 |
Why?
| | Eye Abnormalities | 1 | 2020 | 24 | 0.170 |
Why?
| | Eyeglasses | 1 | 2019 | 9 | 0.160 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 522 | 0.160 |
Why?
| | Vitreoretinal Surgery | 1 | 2019 | 8 | 0.160 |
Why?
| | Disease Management | 1 | 2021 | 188 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2019 | 46 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 182 | 0.160 |
Why?
| | Optic Disk | 1 | 2019 | 20 | 0.160 |
Why?
| | Crohn Disease | 1 | 2020 | 117 | 0.160 |
Why?
| | Pandemics | 1 | 2024 | 585 | 0.160 |
Why?
| | Biopsy | 1 | 2021 | 605 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 82 | 0.150 |
Why?
| | Amaurosis Fugax | 1 | 2018 | 3 | 0.150 |
Why?
| | Vision, Ocular | 1 | 2018 | 10 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 154 | 0.150 |
Why?
| | Glucosylceramidase | 1 | 2018 | 8 | 0.150 |
Why?
| | Retinal Artery Occlusion | 1 | 2018 | 13 | 0.150 |
Why?
| | Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.150 |
Why?
| | Infant | 2 | 2024 | 3733 | 0.150 |
Why?
| | Visual Fields | 1 | 2018 | 41 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2020 | 103 | 0.150 |
Why?
| | Fluocinolone Acetonide | 1 | 2017 | 5 | 0.140 |
Why?
| | Prone Position | 1 | 2017 | 32 | 0.140 |
Why?
| | Thrombolytic Therapy | 1 | 2018 | 110 | 0.140 |
Why?
| | Genes, Recessive | 1 | 2017 | 16 | 0.140 |
Why?
| | Consanguinity | 1 | 2017 | 18 | 0.140 |
Why?
| | Uveitis | 1 | 2017 | 23 | 0.140 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 128 | 0.140 |
Why?
| | Ophthalmology | 2 | 2018 | 33 | 0.140 |
Why?
| | Heterozygote | 1 | 2017 | 90 | 0.140 |
Why?
| | Phenotype | 1 | 2020 | 789 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2018 | 483 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 180 | 0.130 |
Why?
| | Air | 1 | 2016 | 23 | 0.130 |
Why?
| | Minerals | 1 | 2016 | 26 | 0.130 |
Why?
| | Genetic Association Studies | 1 | 2017 | 122 | 0.130 |
Why?
| | Sodium Chloride | 1 | 2016 | 56 | 0.130 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 166 | 0.130 |
Why?
| | Acetates | 1 | 2016 | 52 | 0.130 |
Why?
| | United States | 2 | 2024 | 5192 | 0.130 |
Why?
| | Equipment Failure | 1 | 2016 | 64 | 0.120 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 69 | 0.120 |
Why?
| | Adolescent | 3 | 2022 | 6739 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 235 | 0.120 |
Why?
| | Eye Foreign Bodies | 1 | 2015 | 6 | 0.120 |
Why?
| | Nevus of Ota | 1 | 2014 | 2 | 0.120 |
Why?
| | Scleral Diseases | 1 | 2014 | 2 | 0.120 |
Why?
| | Eye Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
| | Siblings | 1 | 2014 | 34 | 0.110 |
Why?
| | Vision, Monocular | 1 | 2013 | 1 | 0.110 |
Why?
| | Injections, Intraocular | 1 | 2013 | 2 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2018 | 333 | 0.110 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2013 | 11 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 81 | 0.110 |
Why?
| | Animals | 4 | 2022 | 13505 | 0.110 |
Why?
| | Molecular Biology | 2 | 2023 | 27 | 0.100 |
Why?
| | Cell Line | 1 | 2016 | 1030 | 0.100 |
Why?
| | GTP-Binding Proteins | 2 | 2023 | 85 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2020 | 5422 | 0.100 |
Why?
| | Activities of Daily Living | 1 | 2013 | 182 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2024 | 1068 | 0.100 |
Why?
| | Autistic Disorder | 1 | 2013 | 126 | 0.100 |
Why?
| | Diet | 1 | 2016 | 587 | 0.090 |
Why?
| | Endotoxins | 1 | 2011 | 21 | 0.090 |
Why?
| | Rats, Inbred Lew | 1 | 2011 | 48 | 0.090 |
Why?
| | Administration, Topical | 1 | 2011 | 61 | 0.090 |
Why?
| | Cornea | 1 | 2011 | 53 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2013 | 292 | 0.090 |
Why?
| | Pseudomonas aeruginosa | 1 | 2011 | 78 | 0.090 |
Why?
| | Membrane Proteins | 2 | 2023 | 335 | 0.090 |
Why?
| | RNA | 1 | 2011 | 168 | 0.090 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 1884 | 0.090 |
Why?
| | Mice | 2 | 2022 | 5949 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 582 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 2 | 2020 | 183 | 0.080 |
Why?
| | Cytokines | 1 | 2011 | 623 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 1678 | 0.070 |
Why?
| | Internship and Residency | 1 | 2013 | 448 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1546 | 0.070 |
Why?
| | Aptamers, Nucleotide | 1 | 2006 | 8 | 0.060 |
Why?
| | Vitamins | 1 | 2006 | 64 | 0.060 |
Why?
| | Aged, 80 and over | 2 | 2020 | 3392 | 0.060 |
Why?
| | Rats | 1 | 2011 | 3220 | 0.060 |
Why?
| | Microvessels | 1 | 2024 | 31 | 0.060 |
Why?
| | Atrophy | 1 | 2023 | 45 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 43 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 16 | 0.050 |
Why?
| | Recovery of Function | 1 | 2023 | 199 | 0.050 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2002 | 2 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2024 | 406 | 0.050 |
Why?
| | Vitreous Body | 1 | 2002 | 19 | 0.050 |
Why?
| | Injections | 1 | 2002 | 61 | 0.050 |
Why?
| | Smoking | 1 | 2006 | 520 | 0.050 |
Why?
| | Lipids | 1 | 2022 | 155 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 240 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 251 | 0.050 |
Why?
| | Hypertension | 1 | 2006 | 565 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 610 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2023 | 215 | 0.040 |
Why?
| | Epiretinal Membrane | 1 | 2020 | 10 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2023 | 299 | 0.040 |
Why?
| | Mitochondria | 1 | 2022 | 430 | 0.040 |
Why?
| | State Medicine | 1 | 2018 | 17 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 293 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 12 | 0.040 |
Why?
| | Lens Implantation, Intraocular | 1 | 2018 | 23 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2018 | 78 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 625 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 132 | 0.030 |
Why?
| | Video Recording | 1 | 2016 | 81 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2018 | 268 | 0.030 |
Why?
| | Time Factors | 1 | 2019 | 2968 | 0.030 |
Why?
|
|
Uwaydat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|